Evidence map›Paper›PMID 33674295›Full record

ArticleBMJ case reports2021

Deep vein thrombosis on the fourth day of risperidone therapy.

Kavitha Konnakkaparambil Ramakrishnan, Mithila George

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Kavitha Konnakkaparambil RamakrishnanDepartment of Psychiatry, Government TD Medical College, Alapuzha, Kerala, India drkavithamadhavan@gmail.com.ORCID http://orcid.org/0000-0002-0725-2484
Mithila GeorgeDepartment of Psychiatry, Government Medical College, Ernakulam, Cochin, Kerala, India.ORCID http://orcid.org/0000-0001-5411-532X
Government Medical College · INT. D. Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep vein thrombosis has been recognised as a complication of antipsychotic treatment and is reported to be more common with atypical antipsychotics. Risperidone is a second-generation atypical antipsychotic and there have been case reports of risperidone-associated deep vein thrombosis, most of them reporting the complication from 2 weeks to a few months of initiation of therapy. Here, we are reporting a case of deep vein thrombosis in a male patient in his early forties with paranoid schizophrenia, which presented on the fourth day of starting risperidone therapy. This case is being reported to highlight the fact that deep vein thrombosis can occur as early as fourth day of initiation of risperidone therapy, that too at a low dose (2 mg/day). The case also emphasises the importance of monitoring these patients for this rare but potentially serious adverse effect from the first day itself after initiation of a new antipsychotic.

Indexed as

Antipsychotic AgentsVenous ThrombosisBenzodiazepinesHumansMaleRisperidoneSchizophrenia, ParanoidAntipsychotic AgentsBenzodiazepinesRisperidonedrugs: psychiatrypsychiatry (drugs and medicines)unwanted effects / adverse reactions

Identifiers

PMID33674295
PMCPMC7938988
OpenAlexW3134632199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.